Hepatocyte growth factor as a long‑term predictor for total and cardiovascular mortality in patients on peritoneal dialysis.

INTRODUCTION  Hepatocyte growth factor (HGF) is a regenerative protein involved in tissue protection and endothelial repair in response to injury. OBJECTIVES  The aim of the study was to assess the effect of increased HGF levels on total and cardiovascular (CV) mortality in patients on peritoneal dialysis (PD) during 6‑year follow‑up. PATIENTS AND METHODS  The study included 55 patients (mean age, 53 years; median duration of PD, 24 months). The ejection fraction (EF) and calcium score (CaSc) were measured. White blood cell (WBC) count and albumin, calcium (Ca), phosphorus (Pi), intact parathormone (iPTH), and high‑sensitivity C‑reactive protein (hsCRP) levels were measured. Serum levels of HGF, interleukin (IL) 6, and IL‑18 were determined using enzyme‑linked immunosorbent assays. RESULTS  Of all patients, 45% died within 6 years, including 80% from CV complications. HGF significantly correlated with the total (hazard ratio [HR], 1.97; P = 0.03) and CV (HR, 2.04; P = 0.04) mortality in a univariate Cox regression model. This was confirmed by a multiple model including age, dialysis duration, residual renal function (RRF), albumin, Ca × Pi, EF, and CaSc (HR, 2.24; P = 0.02 and HR, 2.58; P = 0.02 for total and CV mortality, respectively). Factors negatively affecting patients' survival included WBC count, hsCRP, IL‑6, and CaSc, while higher albumin levels and EF were associated with longer overall survival. HGF positively correlated with WBC count (r = 0.30, P = 0.01), hsCRP (r = 0.25, P = 0.04), IL‑6 (r = 0.46, P = 0.0004), CaSc (r = 0.29, P = 0.03), and mean arterial pressure (r = 0.25; P = 0.04) and negatively with RRF (r = -0.31, P = 0.02). CONCLUSIONS  Increased concentrations of proinflammatory cytokines and an association between HGF levels and CaSc may indicate higher total and CV mortality in patients on PD.

[1]  M. Tendera,et al.  Coronary artery calcium in type 2 diabetes: a nested case‑control study. , 2012, Polskie Archiwum Medycyny Wewnetrznej.

[2]  C. Lam,et al.  A Study of the Clinical and Biochemical Profile of Peritoneal Dialysis Fluid Low in Glucose Degradation Products , 2012, Peritoneal Dialysis International.

[3]  R. de Caterina,et al.  Hepatocyte growth factor: Molecular biomarker and player in cardioprotection and cardiovascular regeneration , 2012, Thrombosis and Haemostasis.

[4]  Michiel L Bots,et al.  Added value of CAC in risk stratification for cardiovascular events: a systematic review , 2012, European journal of clinical investigation.

[5]  D. Duś,et al.  Endostatin and vascular endothelial growth factor: potential regulators of endothelial progenitor cell number in chronic kidney disease. , 2011, Polskie Archiwum Medycyny Wewnetrznej.

[6]  F. Lallemand,et al.  Arteriogenic Therapy by Intramyocardial Sustained Delivery of a Novel Growth Factor Combination Prevents Chronic Heart Failure , 2011, Circulation.

[7]  K. Huber,et al.  Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure , 2011, Heart.

[8]  K. Ciechanowski,et al.  Urinary hepatocyte growth factor indicates ischemia/reperfusion injury after kidney transplantation. , 2010, Polskie Archiwum Medycyny Wewnetrznej.

[9]  Chien-Te Lee,et al.  Proinflammatory cytokines, hepatocyte growth factor and adipokines in peritoneal dialysis patients. , 2010, Artificial organs.

[10]  W. Gao,et al.  HEPATOCYTE GROWTH FACTOR PLAYS A CRITICAL ROLE IN THE REGULATION OF CYTOKINE PRODUCTION AND INDUCTION OF ENDOTHELIAL PROGENITOR CELL MOBILIZATION: A PILOT GENE THERAPY STUDY IN PATIENTS WITH CORONARY HEART DISEASE , 2009, Clinical and experimental pharmacology & physiology.

[11]  Sun-Hee Park,et al.  HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. , 2009, Journal of the American Society of Nephrology : JASN.

[12]  M. Myśliwiec,et al.  [Relevance of some growth factors to cardiovascular disease in maintenance hemodialysis patients]. , 2006, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[13]  N. Lamblin,et al.  Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. , 2005, American heart journal.

[14]  C. Zoccali,et al.  Hepatocyte Growth Factor and Left Ventricular Geometry in End-Stage Renal Disease , 2003, Hypertension.

[15]  M. Aoki,et al.  Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease. , 2002, Endocrine journal.

[16]  J. Borawski,et al.  Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  C. Zoccali,et al.  Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  U. Ikeda,et al.  Production of hepatocyte growth factor during acute myocardial infarction , 2000, Heart.

[19]  J. Chudek,et al.  Biomarkers of calcification and atherosclerosis in patients with degenerative aortic stenosis in relation to concomitant coronary artery disease. , 2012, Polskie Archiwum Medycyny Wewnetrznej.

[20]  J. Miyazaki,et al.  Hepatocyte growth factor gene therapy for hypertension. , 2008, Methods in molecular biology.